Logo image of GANX

GAIN THERAPEUTICS INC (GANX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GANX - US36269B1052 - Common Stock

4.05 USD
+0.06 (+1.5%)
Last: 12/9/2025, 1:07:53 PM
Fundamental Rating

1

Taking everything into account, GANX scores 1 out of 10 in our fundamental rating. GANX was compared to 531 industry peers in the Biotechnology industry. While GANX seems to be doing ok healthwise, there are quite some concerns on its profitability. GANX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

GANX had negative earnings in the past year.
GANX had a negative operating cash flow in the past year.
In the past 5 years GANX always reported negative net income.
GANX had a negative operating cash flow in each of the past 5 years.
GANX Yearly Net Income VS EBIT VS OCF VS FCFGANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

GANX's Return On Assets of -168.36% is on the low side compared to the rest of the industry. GANX is outperformed by 88.14% of its industry peers.
With a Return On Equity value of -278.10%, GANX is not doing good in the industry: 72.50% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -168.36%
ROE -278.1%
ROIC N/A
ROA(3y)-120.33%
ROA(5y)-86.78%
ROE(3y)-182.77%
ROE(5y)-129.19%
ROIC(3y)N/A
ROIC(5y)N/A
GANX Yearly ROA, ROE, ROICGANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

GANX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GANX Yearly Profit, Operating, Gross MarginsGANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K -40K

More info and screens

4

2. Health

2.1 Basic Checks

GANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
GANX has more shares outstanding than it did 1 year ago.
GANX has more shares outstanding than it did 5 years ago.
GANX has a worse debt/assets ratio than last year.
GANX Yearly Shares OutstandingGANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
GANX Yearly Total Debt VS Total AssetsGANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

GANX has an Altman-Z score of 5.09. This indicates that GANX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.09, GANX is in the better half of the industry, outperforming 72.69% of the companies in the same industry.
GANX has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.04, GANX is in line with its industry, outperforming 40.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 5.09
ROIC/WACCN/A
WACC8.76%
GANX Yearly LT Debt VS Equity VS FCFGANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

GANX has a Current Ratio of 2.97. This indicates that GANX is financially healthy and has no problem in meeting its short term obligations.
GANX has a worse Current ratio (2.97) than 65.54% of its industry peers.
GANX has a Quick Ratio of 2.97. This indicates that GANX is financially healthy and has no problem in meeting its short term obligations.
GANX has a Quick ratio of 2.97. This is in the lower half of the industry: GANX underperforms 63.09% of its industry peers.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.97
GANX Yearly Current Assets VS Current LiabilitesGANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.86% over the past year.
GANX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)47.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

GANX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.02% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y28.67%
EPS Next 2Y7.36%
EPS Next 3Y-0.26%
EPS Next 5Y10.02%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GANX Yearly Revenue VS EstimatesGANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2029 2030 2031 2032 100M 200M 300M
GANX Yearly EPS VS EstimatesGANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GANX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GANX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GANX Price Earnings VS Forward Price EarningsGANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GANX Per share dataGANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.36%
EPS Next 3Y-0.26%

More info and screens

0

5. Dividend

5.1 Amount

GANX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GAIN THERAPEUTICS INC

NASDAQ:GANX (12/9/2025, 1:07:53 PM)

4.05

+0.06 (+1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-25 2026-03-25/amc
Inst Owners11.57%
Inst Owner Change14.62%
Ins Owners2.77%
Ins Owner Change0%
Market Cap155.76M
Revenue(TTM)N/A
Net Income(TTM)-20.41M
Analysts85.45
Price Target6.94 (71.36%)
Short Float %5.12%
Short Ratio1.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.83%
Min EPS beat(2)22.48%
Max EPS beat(2)41.18%
EPS beat(4)3
Avg EPS beat(4)-3.99%
Min EPS beat(4)-105.88%
Max EPS beat(4)41.18%
EPS beat(8)4
Avg EPS beat(8)-13.95%
EPS beat(12)6
Avg EPS beat(12)-8.59%
EPS beat(16)8
Avg EPS beat(16)-12.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-15%
PT rev (3m)-11.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)1.03%
EPS NY rev (3m)-3.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 21.22
P/tB 21.62
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-0.49
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -168.36%
ROE -278.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-120.33%
ROA(5y)-86.78%
ROE(3y)-182.77%
ROE(5y)-129.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.97
Altman-Z 5.09
F-Score1
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)81.72%
Cap/Depr(5y)179.04%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
EPS Next Y28.67%
EPS Next 2Y7.36%
EPS Next 3Y-0.26%
EPS Next 5Y10.02%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.04%
OCF growth 3YN/A
OCF growth 5YN/A

GAIN THERAPEUTICS INC / GANX FAQ

Can you provide the ChartMill fundamental rating for GAIN THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to GANX.


What is the valuation status for GANX stock?

ChartMill assigns a valuation rating of 0 / 10 to GAIN THERAPEUTICS INC (GANX). This can be considered as Overvalued.


Can you provide the profitability details for GAIN THERAPEUTICS INC?

GAIN THERAPEUTICS INC (GANX) has a profitability rating of 0 / 10.


What is the financial health of GAIN THERAPEUTICS INC (GANX) stock?

The financial health rating of GAIN THERAPEUTICS INC (GANX) is 4 / 10.


What is the expected EPS growth for GAIN THERAPEUTICS INC (GANX) stock?

The Earnings per Share (EPS) of GAIN THERAPEUTICS INC (GANX) is expected to grow by 28.67% in the next year.